Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Novel mouse model to investigate the pathophysiology of alpha-thalassemia

Stefano Rivella, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, shares some insights into a novel mouse model which has been developed for alpha-thalassemia, and has allowed researchers to better understand the pathophysiology of this disease and explore novel treatment approaches. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


BVF Partners L.P: Consultancy; Cambridge Healthcare Res: Consultancy; Catenion: Consultancy; Celgene: Consultancy; Disc Medicine: Current holder of stock options in a privately-held company, Membership on an entity’s Board of Directors or advisory committees; First Manhattan Co: Consultancy; FORMA: Consultancy; Ghost Tree Capita: Consultancy; Incyte: Membership on an entity’s Board of Directors or advisory committees; Ionis Pharmaceuticals: Membership on an entity’s Board of Directors or advisory committees; Keros Therapeutics: Consultancy; MeiraGTx: Consultancy; Noble insight: Consultancy; Protagonist Therapeutics: Consultancy; Rallybio, LLC: Consultancy; Sanofi Aventis U.S: Consultancy; Slingshot Insight: Consultancy; Consultancy; venBio Select LLC: Consultancy; Vifor: Membership on an entity’s Board of Directors or advisory committees.